this quantity of test monkeys for the pharmaceutical industry China is shrinking significantly, which means shortage in the industry and a corresponding increase in prices, according to several local financial media.
That’s why pharmaceutical companies buy Cynomolgus monkeys, also known as Cynomolgus monkeys. crab-eating macaques: Last Monday, Joinn announced the acquisition of the lab. Yingmiao Biological, An animal supplier with 20,000 specimens of this species.
As the unit value of these monkeys has increased from 7,000 yuan ($1,047, 985 euros) to 160,000 yuan in 2014, it is a business that has become lucrative because of the companies’ need to have these animals for clinical testing. 23,942 dollars, 22,515 euros) today, an increase of more than 23 times in seven years.
Combined with the high demand and scarcity of these crab-eating macaques most commonly used for these tests – it is currently estimated that there are only 30,000 macaques available for testing in the entire Chinese region – that pharmaceutical companies devoted themselves to “monkey hoarding”, According to the Chinese Experimental Primate Breeding and Development Association, they were found to be more effective for drug testing than mice and rabbits.
By sharing 90-93% of the genetic code with humansare ideal subjects for medical experimentstherefore, a business of monkey farms was created, mostly in Southeast Asia, which supplied them to research and development laboratories and did not get them until the age of three.
Since the emergence of Covid-19, many These are Chinese pharmaceutical companies that are developing vaccines using experimental monkeys. For clinical trials, although some analysts say experimental monkey boredom may ease as the impact of the pandemic wanes.
China maintains strict policy of prevention against covid consisting of almost complete closure of borders, isolation of all infected in quarantine centers and large PCR tests and restriction of movements wherever a case is detected.